The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

Diabetes India has announced a nationwide campaign for early detection of Chronic Kidney Disease (CKD) in diabetes patients.

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Our study thus confirmed what was found in people of African descent in the US: the genetic origin underpinning the excess ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for fo ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

Denmark: A recent study published in the Journal of Diabetes and its Complications has explored the role of kidney fat ...